IMU-838 45 mg tablet

DRUG2 trials

Sponsors

Goethe University Frankfurt, Immunic AG

Conditions

Post Covid Syndrome (PCS)Progressive forms of Multiple Sclerosis

Phase 2

Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

CompletedCTIS2024-511628-16-00

Goethe University FrankfurtPost Covid Syndrome (PCS)

Start: 2024-07-18End: 2025-09-30Target: 376Updated: 2025-05-09

P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)

RecruitingCTIS2024-514617-35-00

Immunic AGProgressive forms of Multiple Sclerosis

Start: 2021-12-20Target: 230Updated: 2025-04-03

Related Papers

Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).

2025-08-191 citations